Effects of Growth Hormone on Muscle and Bone in Female Mice: Role of Follistatin

Abstract

The interactions between muscle and bone are noted in the clinical relationships between sarcopenia and osteoporosis. Myokines secreted from the skeletal muscles play roles in muscle-bone interactions related to various physiological and pathophysiological states. Although numerous evidence suggests that growth hormone (GH) influences both muscle and bone, the effects of GH on the muscle-bone interactions have remained unknown. We, therefore, investigated the influences of GH administration for 8 weeks on muscle and bone, including myokine expression, in mice with or without ovariectomy (OVX). GH administration significantly increased muscle mass in the whole body and lower limbs, as well as tissue weights of the extensor digitorum longus (EDL) and soleus muscles in mice with or without OVX. Moreover, it markedly increased grip strength in both mice. As for femurs, GH administration significantly increased cortical thickness and area in mice with or without OVX. Moreover, GH significantly blunted the decrease in the ratio of bone volume to tissue volume at the trabecular bone in mice with OVX. GH administration significantly decreased follistatin mRNA levels in the EDL, but not the soleus, muscles in mice with or without OVX, although it did not affect the other myokines examined. However, GH administration significantly elevated serum follistatin levels in mice. In conclusion, this study indicates that GH administration increases skeletal muscle mass and grip strength and cortical and trabecular bone-related parameters obtained by micro-computed tomography analyses in mice. However, myokine regulation might not be critical for the effects of GH on muscle and bone.

Key words

Growth hormone - Myokine - Muscle - Bone

Publication History

Received: 14 August 2022

Accepted: 22 December 2022

Accepted Manuscript online:
22 December 2022

Article published online:
13 April 2023

• References

• 1 Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119: 3189-3202
• 2 Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med 2019; 380: 2551-2562
• 3 Ranke MB, Wit JM. Growth hormone – past, present and future. Nat Rev Endocrinol 2018; 14: 285-300
• 4 Kaji H, Sugimoto T, Nakaoka D. et al. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf) 2001; 55: 175-181
• 5 Díez JJ, Sangiao-Alvarellos S, Cordido F. Treatment with growth hormone for adults with growth hormone deficiency syndrome: Benefits and risks. Int J Mol Sci 2018; 19: 893
• 6 Rossini A, Lanzi R, Galeone C. et al. Bone and body composition analyses by DXA in adults with GH deficiency: Effects of long-term replacement therapy. Endocrine 2021; 74: 666-675
• 7 Kawao N, Kaji H. Interactions between muscle tissues and bone metabolism. J Cell Biochem 2015; 116: 687-695
• 8 Kaji H. Effects of myokines on bone. Bonekey Rep 2016; 5: 826
• 9 Kawaguchi M, Kawao N, Muratani M. et al. Role of peripheral myelin protein 22 in chronic exercise-induced interactions of muscle and bone in mice. J Cell Physiol 2022; 237: 2492-2502
• 10 Kawao N, Iemura S, Kawaguchi M. et al. Role of irisin in effects of chronic exercise on muscle and bone in ovariectomized mice. J Bone Miner Metab 2021; 39: 547-557
• 11 Kawao N, Morita H, Iemura S. et al. Roles of Dkk2 in the linkage from muscle to bone during mechanical unloading in mice. Int J Mol Sci 2020; 21: 2547
• 12 Kawao N, Morita H, Obata K. et al. Role of follistatin in muscle and bone alterations induced by gravity change in mice. J Cell Physiol 2018; 233: 1191-1201
• 13 Kawao N, Moritake A, Tatsumi K. et al. Roles of Irisin in the linkage from muscle to bone during mechanical unloading in mice. Calcif Tissue Int 2018; 103: 24-34
• 14 Tamura Y, Fujito H, Kawao N. et al. Vitamin D deficiency aggravates diabetes-induced muscle wasting in female mice. Diabetol Int 2016; 8: 52-58
• 15 Tamura Y, Kawao N, Shimoide T. et al. Role of plasminogen activator inhibitor-1 in glucocorticoid-induced muscle change in mice. J Bone Miner Metab 2018; 36: 148-156
• 16 Iemura S, Kawao N, Okumoto K. et al. Role of irisin in androgen-deficient muscle wasting and osteopenia in mice. J Bone Miner Metab 2020; 38: 161-171
• 17 Kawao N, Kawaguchi M, Ohira T. et al. Renal failure suppresses muscle irisin expression, and irisin blunts cortical bone loss in mice. J Cachexia Sarcopenia Muscle 2022; 13: 758-771
• 18 Bouxsein ML, Boyd SK, Christiansen BA. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010; 25: 1468-1486
• 19 Aroniadou-Anderjaska V, Lemon PW, Gilloteaux J. Effects of exogenous growth hormone on skeletal muscle of young female rats. Tissue Cell 1996; 28: 719-724
• 20 Carmeli E, Hochberg Z, Livne E. et al. Effect of growth hormone on gastrocnemius muscle of aged rats after immobilization: biochemistry and morphology. J Appl Physiol (1985) 1993; 75: 1529-1535
• 21 Lopez J, Quan A, Budihardjo J. et al. Growth hormone improves nerve regeneration, muscle re-innervation, and functional outcomes after chronic denervation injury. Sci Rep 2019; 9: 3117
• 22 Roy RR, Tri C, Grossman EJ. et al. IGF-I, growth hormone, and/or exercise effects on non-weight-bearing soleus of hypophysectomized rats. J Appl Physiol (1985) 1996; 81: 302-311
• 23 Santos DP, Okoshi K, Moreira VO. et al. Growth hormone attenuates skeletal muscle changes in experimental chronic heart failure. Growth Horm IGF Res 2010; 20: 149-155
• 24 Verhaeghe J, van Bree R, Van Herck E. et al. Effects of recombinant human growth hormone and insulin-like growth factor-I, with or without 17β-estradiol, on bone and mineral homeostasis of aged ovariectomized rats. J Bone Miner Res 1996; 11: 1723-1735
• 25 Mosekilde L, Thomsen JS, Orhii PB. et al. Growth hormone increases vertebral and femoral bone strength in osteopenic, ovariectomized, aged rats in a dose-dependent and site-specific manner. Bone 1998; 23: 343-352
• 26 Kristensen E, Hallgrímsson B, Morck DW. et al. Timing of growth hormone treatment affects trabecular bone microarchitecture and mineralization in growth hormone deficient mice. Bone 2010; 47: 295-300
• 27 Kristensen E, Hallgrímsson B, Morck DW. et al. Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int J Endocrinol 2012; 2012: 294965
• 28 Kesavan C, Bajwa NM, Watt H. et al. Growth hormone effects on bone loss-induced by mild traumatic brain injury and/or hind limb unloading. Sci Rep 2019; 9: 18995
• 29 Hemmati-Brivanlou A, Kelly OG, Melton DA. Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell 1994; 77: 283-295
• 30 Iemura S, Yamamoto TS, Takagi C. et al. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci USA 1998; 95: 9337-9342
• 31 Khalil AM, Dotimas H, Kahn J. et al. Differential binding activity of TGF-β family proteins to select TGF-β receptors. J Pharmacol Exp Ther 2016; 358: 423-430
• 32 Schneyer AL, Sidis Y, Gulati A. et al. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology 2008; 149: 4589-4595
• 33 Chan ASM, McGregor NE, Poulton IJ. et al. Bone geometry is altered by follistatin-induced muscle growth in young adult male mice. JBMR Plus 2021; 5: e10477
• 34 Lee SJ.. Quadrupling muscle mass in mice by targeting TGF-β signaling pathways. PLoS One 2007; 2: e789
• 35 Suh J, Kim NK, Lee SH. et al. GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone. Proc Natl Acad Sci USA 2020; 117: 4910-4920
• 36 Lodberg A, van der Eerden BCJ, Boers-Sijmons B. et al. A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice. FASEB J 2019; 33: 6001-6010
• 37 Gajos-Michniewicz A, Pawlowska E, Ochedalski T. et al. The influence of follistatin on mechanical properties of bone tissue in growing mice with overexpression of follistatin. J Bone Miner Metab 2012; 30: 426-433
• 38 Hansen J, Brandt C, Nielsen AR. et al. Exercise induces a marked increase in plasma follistatin: Evidence that follistatin is a contraction-induced hepatokine. Endocrinology 2011; 152: 164-171
• 39 Bielohuby M, Schaab M, Kummann M. et al. Serum IGF-I is not a reliable pharmacodynamic marker of exogenous growth hormone activity in mice. Endocrinology 2011; 152: 4764-4776
• 40 Iida K, Itoh E, Kim DS. et al. Muscle mechano growth factor is preferentially induced by growth hormone in growth hormone-deficient lit/lit mice. J Physiol 2004; 560: 341-349
• 41 Rigamonti AE, Locatelli L, Cella SG. et al. Muscle expressions of MGF, IGF-IEa, and myostatin in intact and hypophysectomized rats: Effects of rhGH and testosterone alone or combined. Horm Metab Res 2009; 41: 23-29
• 42 Yoon SH, Grynpas MD, Mitchell J. et al. Growth hormone increases bone toughness and decreases muscle inflammation in glucocorticoid-treated mdx mice, model of Duchenne muscular dystrophy. J Bone Miner Res 2019; 34: 1473-1486